US Bancorp DE Sells 1,463 Shares of Repligen Corporation $RGEN

US Bancorp DE cut its stake in Repligen Corporation (NASDAQ:RGEN) by 13.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 9,165 shares of the biotechnology company’s stock after selling 1,463 shares during the period. US Bancorp DE’s holdings in Repligen were worth $1,140,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in RGEN. Twin Tree Management LP acquired a new position in Repligen in the 1st quarter worth $29,000. Signaturefd LLC boosted its stake in Repligen by 65.3% in the 1st quarter. Signaturefd LLC now owns 324 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 128 shares during the period. Center for Financial Planning Inc. boosted its stake in Repligen by 110.3% in the 1st quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 193 shares during the period. GAMMA Investing LLC boosted its stake in Repligen by 40.1% in the 1st quarter. GAMMA Investing LLC now owns 958 shares of the biotechnology company’s stock worth $122,000 after purchasing an additional 274 shares during the period. Finally, Harvest Fund Management Co. Ltd acquired a new position in Repligen in the 1st quarter worth $132,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Trading Down 1.3%

Shares of RGEN stock opened at $152.60 on Friday. The firm has a 50 day moving average price of $128.81 and a two-hundred day moving average price of $126.33. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $8.59 billion, a PE ratio of -610.38, a price-to-earnings-growth ratio of 2.86 and a beta of 1.08. Repligen Corporation has a 12-month low of $102.96 and a 12-month high of $182.52.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.03). The company had revenue of $182.37 million for the quarter, compared to analyst estimates of $174.62 million. Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The company’s revenue was up 14.8% on a year-over-year basis. During the same quarter last year, the business earned $0.40 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, analysts predict that Repligen Corporation will post 1.72 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on RGEN shares. Stephens raised shares of Repligen to an “overweight” rating and set a $160.00 target price for the company in a research note on Tuesday, July 22nd. Jefferies Financial Group decreased their price objective on Repligen from $145.00 to $135.00 and set a “hold” rating for the company in a report on Friday, September 12th. Royal Bank Of Canada restated an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a report on Tuesday, September 2nd. HSBC began coverage on Repligen in a report on Wednesday, October 1st. They issued a “buy” rating and a $150.00 price objective for the company. Finally, Hsbc Global Res upgraded Repligen to a “strong-buy” rating in a report on Wednesday, October 1st. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Repligen has an average rating of “Moderate Buy” and a consensus target price of $169.62.

Insider Transactions at Repligen

In related news, Director Martin D. Madaus acquired 1,800 shares of the business’s stock in a transaction on Friday, August 8th. The stock was purchased at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the completion of the transaction, the director directly owned 1,800 shares of the company’s stock, valued at approximately $201,834. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.20% of the stock is owned by company insiders.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.